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THE cytokines interleukin-8 (IL-8) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) en-
hanced the extracellular release of arachidonate meta-
bolites from ionophore-stimulated neutrophils by 145 +
10% (mean + S.E.M., n 13) and 182 + 11% (n 16), re-
spectively. To determine whether enhanced leukotriene
production mediates the effects of these cytokines on
neutrophil activity, two different specific arachidonate 5-
lipoxygenase (5-LO) inhibitors, piriprost and MK-886,
were used to inhibit leukotriene synthesis. Neither in-
hibitor affected the upregulation of CD11b -integrin
expression or priming of superoxide generation stimulated
by IL-8 and GM-CSF. It is concluded that leukotrienes do
not mediate either the direct or priming effects of these
cytokines and that these classes of anti-inflammatory
drugs are therefore unlikely to inhibit the effects of IL-8
and GM-CSF on neutrophil activation.
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Introduction
The cytokines granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-8
(IL-8) are potent modulators of neutrophil
function. Both GM-CSF and IL-8 stimulate
increased fle-integrin expression, 1-3 a direct effect.
They also have indirect effects, for example, at
concentrations that are not directly stimulatory,
they enhance or ’prime’ superoxide production
subsequently stimulated by a second agonist. 1’4-6
The biochemical pathways which these cytokines
use are not fully elucidated. Phospholipase A2
activity may mediate some effects of GM-CSF, as
this cytokine stimulates both the release of
metabolites from phospholipids labelled with
3H-arachidonate7-9 and the synthesis of platelet-
activating factor. 1-12 However, IL-8 does not
trigger the synthesis of these compounds. 3-1s
5-Lipoxygenase (5-LO) activity may also mediate
GM-CSF effects as GM-CSF directly stimulates the
release of leukotriene g4 (LTB4),1 although others
have not confirmed these observations.2’6 Exogen-
ous LTB4 increases phagocyte CD11b fl2-integrin
expression,7 therefore increased eicosanoid syn-
thesis may mediate the GM-CSF directed upregula-
tion of CD11b. IL-8 does not directly stimulate
LTB4 synthesis, but can do so when cells are given
exogenous arachidonate 5 min before stimulation
with IL-8.
However, both IL-8 and GM-CSF increase 5-LO
activity in response to other agonists,8’12’6’18 and
this may contribute to the priming effect of these
cytokines on the respiratory burst.6 This is because
the products of 5-LO, 5-hydroxyeicosatetraenoic
acid (5-HETE)9 and LTB420’21 themselves poten-
tiate superoxide production. A recent study of
respiratory burst priming showed that partial
inhibition of 5-LO, did not prevent respiratory
burst priming by either TNFz or GM-CSF,.2 but
because LTB4 release was inhibited by less than
70%, these data are inconclusive.
To examine whether leukotriene synthesis is
involved in either the direct or indirect priming
activities of GM-CSF and 1L-8, measurements were
made of cytokine-stimulated changes in the
expression of the 2-integrin CD11b, and cytokine
priming of superoxide generation in human neutro-
phils pretreated with and without either the arachi-
donate 5-LO inhibitor, 6,9-deepoxy-6,9-(phenylimi-
no)-delta6’8-prostaglandin I1, (piriprost),22 or the
five-lipoxygenase activating protein (FLAP) inhibi-
tor, 3- [1- (p- chlorobenzyl)- 5- isopropyl- 3- t- butyl-
thioindol-2-yl]-2,2’-dimethylpropanoic acid, (MK-
886).23 The authors show that cells whose
leukotriene synthesis is virtually abolished have
intact responses to both cytokines.
Materials and Methods
Materials: Recombinant human (rh) IL-8 from
monocytes was a kind of gift of Sandoz
Forschungsinstitut, Vienna, Austria. A stock
solution at 100 #g/ml was prepared in sterile PBS
with 2% foetal calf serum and stored at -80C. A
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1 #g/ml stock solution of rhGM-CSF (expressed in
E. coli and provided by Hoechst UK, Beringwerke,
Marburg, Germany) was prepared in RPMI
medium with 2% (v/v) foetal calf serum and stored
at -20C. Lymphoprep (density= 1.077 g/ml)
was obtained from Nycomed Pharma AS, Oslo,
Norway. Dulbecco’s phosphate buffered saline
(PBS) was from Gibco BRL, Paisley, Scotland. The
Mol CD11b and control IgM antibodies (Coulter
clone) were from Coulter Electronics Ltd., Luton,
Bedfordshire, UK. [5,6,8,9,11,12,14,15-3H]arachi
donic acid was from Amersham International,
Amersham, Buckinghamshire, UK. Piriprost (6,9-
deepoxy- 6, 9 (phenylimino) delta6’8 prostaglandin
11) was a gift from Dr Michael Bach, The Upjohn
Laboratories, Kalamazoo, MI, USA. The FLAP
antagonist, MK-886 (L-663,536) 3-[1-(p-chloro-
benzyl)- 5-isopropyl-3-t-butylhioindol-2-yl]-2,2’-
dimethylpropanoic acid, was a gift from Dr Gillard,
Merck-Frosst Canada Inc., Pointe Claire-Dorval,
Quebec, Canada. C18 (300 mg) Maxi-Clean columns
were from Alltech, Carnforth, Lancashire, UK.
Leukotriene standards were from Cascade Biochem
Ltd, Reading, Berkshire, UK.
NeutrophilpurijScation: Neutrophils were purified from
venous blood anticoagulated with 2 mM EDTA,
pH 7.4 by dextran sedimentation, Lymphoprep
density gradient separation and erythrocyte lysis, as
described previously.4 The purified neutrophils
were suspended in PBS supplemented with 0.9 mM
CaCl2, 0.5 mM MgCl2 and 5 mM D-glucose (PBSG).
CDllb expression: 50/ll aliquots of purified neu-
trophils (1 x 106/ml) were incubated with either
diluent, IL-8 (100 ng/ml), or GM-CSF (10 ng/ml)
for 30 min at 37C. The samples were placed on ice
and CD11b expression was measured by flow
cytometry using direct immunofluorescence with a
mouse IgM FITC-conjugated CD11b monoclonal
antibody (Mol) as described previously.24
Superoxide generation: Cells (1 106/ml) were equi-
librated in 1 ml plastic spectrophotometer cuvettes
for 5 min before addition of cytokines or diluent.
Cells were stimulated with either 1/IM formyl-
methionyl-leucyl-phenyalanine (fMLP) or 1.67/.zM
12- O-tetradecanoylphorbol- 13-acetate (TPA).
Superoxide production by purified neutrophils at
37C was measured by the continuous assay of
superoxide dismutase-inhibitable reduction of ferri-
cytochrome c, as described previously.4
Extracellular release of [3H]arachidonate-labelled metabo-
lites from intracellular arachidonate Purified neu-
trophils (5 x 106/ml PBSG, 0.1% FCS) were
labelled with [3H]arachidonate (202 Ci/mmol) at a
final concentration of 0.5/iCi/ml, for 2 h at 20C
with occasional mixing. Under these conditions
approximately 80% of the isotope was taken into
the cells. The radiolabelled cells were centrifuged
(180 x g, 5 min) and the supernatant containing
unincorporated isotope was removed. The cell
pellet was washed four times in PBSG and finally
resuspended to 2 x 106 cells/ml PBSG. Control
experiments measuring superoxide production
showed that this labelling procedure did not itself
cause priming of neutrophils. 0.5 ml aliquots were
equilibrated to 37C, mixed with either diluent, IL-8
(100 ng/ml), or GM-CSF (10 ng/ml) and incubated
for 30 min at 37C. Arachidonate metabolism was
stimulated with Ca2+ ionophore A23187 (1 #M)
for 7 min and the reaction was terminated by
placing the samples on ice. The samples were
centrifuged (12 000 x g’, 2 min) and 0.4 ml aliquots
of the supernatants were assayed for radioactivity
by liquid scintillation spectroscopy. The cell pellets
were lysed with 0.1% Triton-X-100, made up to
0.5 ml volume, and 0.4ml aliquots were also
assayed for radioactivity.
Inhibitors: An 8.7 mM stock solution of the 5-LO
inhibitor, piriprost,22 in distilled water and a
100 #M stock solution of the FLAP antagonist,
MK886,23 in DMSO, were prepared immediately
prior to use. In all experiments described
neutrophils were incubated for 5 min with
inhibitors before priming with cytokines or
stimulation with 1/IM A23187. Dose-response
experiments measuring the release of metabolites
labelled with [H]arachidonate were performed to
determine the optimal final concentration of
inhibitors. Control experiments showed that the
final concentration of DMSO used (0.1% v/v) had
no effect on neutrophil function.
Measurement of leukotriene synthesis: Neutrophils (1
10V/ml, 4 x 10V/sample) were warmed to 37C and
incubated with MK-886 or diluent as described
above and then incubated with or without GM-CSF
(10 ng/ml) for 30 min before stimultion with 1
A23187. The reaction was stopped after 10 min by
addition of 2 vol of ice cold ethanol, followed by
200 ng prostaglandin B2 as internal standard. The
samples were cooled on ice. The samples were
diluted with water to give a final ethanol
concentration of 15% (v/v) and centrifuged at
400 x g for 10 min at 4C. The supernatants were
acidified with formic acid to pH 3.0. Solid phase
extraction of leukotrienes was performed using C18
minicolumns following the method of Powell.is
Eicosanoids were eluted with 5 ml ethyl acetate.
The samples were dried by centrifugal evaporation,
resuspended in 0.5 ml ethyl acetate and transferred
to a 1.5 ml polypropylene container. The samples
were again dried and the pellet was dissolved in
50/il methanol-water (70:30). Eicosanoids were
separated by reverse-phase HPLC (RP-HPLC)
using a Spherisorb C18 column (ODS2, 250 x
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4.6 mm i.d., Phillips Scientific, Cambridge, UK)
attached to a Waters 625 LC system (Millipore UK
Ltd., Watford, Hertfordshire, UK) with a 20 #1
injection loop. The isocratic mobile phase was
methanol :water :acetic acid (67:33:0.1 by vol.),
pH 6.25. The flow rate was 0.75 ml/min and the
effluent was monitored by a Waters 991 photodiode
array detector. Chromatograms were recorded at
270 nm and the eluant peaks were scanned from
190-320 nm. After 60 min, methanol water
(90:10) was mixed with the mobile phase in a
proportion of 1:1, to ensure that all eicosanoids
were eluted from the column. Peaks obtained were
compared with authentic leukotriene standards.
Statistical analysis" Unless otherwise indicated the
standard error of the estimate of the mean value is
given and the statistical test used is the Student’s
t-test for paired samples.
Results
Priming of neutrophil 5-LO activity by IL-8 and
GM-CSF: The major metabolites of endogenous
arachidonate in neutrophils stimulated with the
Ca2+ ionophore, A23187, are the 5-LO products,
5-HETE and LTB4.22 The synthesis of metabolites
from endogenous [3H]arachidonate pools can be
estimated by counting the extracellular radioactivity
released from stimulated cells. Pilot experiments
using thin layer chromatography showed that under
the labelling conditions used 63% of incorporated
[3H]arachidonate was in glycerophospholipid pools
with no detectable free intracellular [3H]arachi-
donate. Table 1 shows the effects of the cytokines,
IL-8 and GM-CSF on the release of radioactivity
from both resting and ionophore-stimulated neutro-
phils. The release of radioactivity stimulated by IL-8
Table 1. Effect of IL-8 and GM-CSF on the extracellular release
of radioactivity from neutrophil phospholipids with [3H]arachi-
donate
Stimulus Release of [3H]arachidonate
metabolites (cpm/106 cells)
IL-8 GM-CSF
(100 ng/ml) (10 ng/ml)
Diluent + 0.01% DMSO
Cytokine + 0.01% DMSO
Diluent + /M A23187
Cytokine + /M A23187
990 _+ 116b 929 _+ 94
(p 0.18) (p 0.003)
062 _+ 142 132 _+ 130
4 514 _+ 592 5 040 _+ 773
(p 0.001 (p 0.001)
5 977 -I- 815 8 505 _+ 1272
aRadiolabelled neutrophils were incubated at 37C for 30 min
with either IL-8, GM-CSF or 2% FCS diluent, and then
stimulated with either A23187 or DMSO diluent.
bThe data shown are the mean -t- S.E.M. for 13 experiments with
IL-8 and 16 experiments with GM-CSF. The significance values
(p) of the differences between paired samples treated with and
without growth factor are given in parentheses.
was not diEerent from control, whereas the release
stimulated by GM-CSF was greater than control by
200 cpm/106 cells (representing 0.5% of total incor-
porated radioactivity), a very minor but statistically
significant difference (p 0.003, n 13). In
samples preincubated for 30 min with cytokine
diluent, 1 M A23187 stimulated the release of
about 4000 cpm/106 ceils greater than background,
which represented on average 9.5% of total
incorporated radioactivity. When neutrophils were
incubated with IL-8 and GM-CSF before stimula-
tion, the release of radioactivity in response to
A23187 was enhanced by 145 10% (n 13) and
182 _+ 11% (n--16), respectively, a statistically
significant increase.
Inhibition of 5-LO activity by piriprost and MK-886:
Experiments were performed to determine the
optimal concentrations of the 5-LO inhibitors,
piriprost and MK-886, in which the release of
[H]arachidonate-labelled metabolites from iono-
phore-stimulated cells was determined as above.
Neutrophils were incubated for 30 min with the
inhibitors at a range of concentrations followed by
stimulation with 1 M A23187. Figure 1 shows that
almost complete inhibition of the release of
radioactivity from unprimed neutrophils was
achieved by piriprost and MK-886. The mean ICs0
for piriprost was 6.3 1.8 HM (n 3) and for
MK-886 was 5.5 _+ 1.7 nM (n 4). In six experi-
ments performed at a single concentration,
the mean inhibition of radioactive release from
unprimed neutrophils was 93 _+ 2% with 100 nM
MK-886 and 95 1% with 87 HM piriprost. The
release of radioactivity from IL-8 primed cells was
similarly inhibited by 95 +_ 1% (n--5) with
100nM MK-886 and by 95_2% (n=3) with
87 M piriprost. To confirm that eicosanoid
synthesis was inhibited in GM-CSF-primed cells
further studies were performed.
Confirmation of the inhibition of 5-1ipoxygenase in GM-CSF
primed cells by piriprost and MK-886 using RP-HPLC" The
authors have previously shown using RP-HPLC
that total cellular leukotriene synthesis and
extracellular release by ionophore-stimulated neu-
trophils is completely inhibited by 87/M piri-
prost.26 In the present study total eicosanoid
production was similarly measured in ionophore-
stimulated cells by extracting both the cells and
supernatants together as described in the methods
and then separating the leukotrienes by RP-HPLC.
Neutrophils were incubated with either 100 nM
MK-886 or 0.1% DMSO for 5 min before exposure
to GM-CSF (10 ng/ml) or diluent for 30 min. All
samples were stimulated with 1 HM A23187 for 10
min. In samples not exposed to MK-886, peaks
were identified that had the spectral characteristics
of LTB4 and its oxidation products, however the
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FIG. 1. Dose-dependent inhibition by piriprost and MK-886 of the release
of [3H]arachidonate metabolites from neutrophils stimulated with #M
A23187. Cells (2 x 106/ml) were incubated with inhibitors or their
respective diluents (H20 and 0.2% DMSO), for 5 min at 37C before
stimulation. Background release was subtracted and the data expressed
as a percentage of the release from control samples incubated with
diluent. The data shown are the mean values of duplicate samples from
single experiments representative of three performed with piriprost and
four with M K-886.
+ MK-886
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FIG. 2. Inhibition of leukotriene synthesis by MK-886 in GM-CSF primed
neutrophils, analysed by RP-HPLC. The two left-hand columns are
chromatograms recorded at 270 nm for neutrophils pre-treated with
(+MK-886) and without (-MK-B86) 100 nM MKBB6, before priming
with GM-CSF and stimulation with /M A23187. Spectral analysis of
the eluant peaks scanned from 220 to 320 nm is shown in the right-hand
column. The peaks shown are: (1) unidentified peak present in all
samples (UVmax 258nm); (2) 20-hydroxy-LTB4 (UVmax 270nm);
(3) prostaglandin B2 (UVma 278nm); (4) and (5) LTB4 metabolites
(UVma 270 nm); (6) LTB4; (7) and (8) further LTB4 metabolites eluted
from the column with methanol (UVmax 270 nm).
peptidoleukotrienes, LTC4, LTD4 and LTE4 were
not detected. Figure 2 shows the data for GM-CSF
primed neutrophils and similar data (not shown)
were obtained with unprimed cells. Figure 2 also
shows the complete inhibition of leukotriene
production in GM-CSF primed neutrophils pre-
incubated with 100 nM MK-886. Similar inhibition
of leukotriene synthesis by MK-886 was seen in
unprimed neutrophils (data not shown).
The eject of 5-go inhibitors on the activity of IL-8 and
GM-CSF
a) Priming of fmLP-stimulated superoxide generation:
Neutrophil superoxide production was measured by
the superoxide dismutase-inhibitable reduction of
ferricytochrome c. Initial experiments showed that
the 5-LO inhibitors, piriprost (87/M) and MK-886
(100 nM), did not inhibit respiratory burst activity
stimulated by 1.67 #M TPA, demonstrating that the
doses used were not toxic to the cells and that these
inhibitors did not inhibit protein kinase c (data not
shown). Neither did piriprost nor MK-886 inhibit
the generation of superoxide stimulated by 1/M
fMLP (Table 2). Table 2 also shows that in
experiments where GM-CSF and IL-8 increased
fMLP-stimulated superoxide production by be-
tween three to five-fold, there was no reduction in
this priming activity when replicate samples were
preincubated with either piriprost or MK-886
before exposure to the cytokines, conditions which
were demonstrated in parallel experiments to give
greater than 90% inhibition of 5-LO activity.
b) Upregulation of CD1 lb expression: Neutrophil CD1 lb
expression was measured by direct immunofluor-
escence, using flow cytometry to determine the
mean cell fluorescence (MCF). Figure 3 shows that
IL-8 rapidly stimulated the increased expression of
CD11b antigen on purified neutrophils. CD11b
expression was upregulated more slowly by
GM-CSF, reaching a maximum by 20 min. When
cells were pre-incubated with either 100nM
MK-886 or 87/M piriprost before exposure to
cytokines, there was no change in either the kinetics
or magnitude of the response (Fig. 3).
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Table 2. Effect of 5-1ipoxygenase inhibitors on the priming of
the fMLP-stimulated neutrophil respiratory burst by IL-8 and
GM-CSF
Treatment Superoxide generation
(nmol/106 cells)
Cytokine + Cytokine
0.2% DMSO _+ GM-CSF 5.4 _+ 1.1 b
MK-886 _+ GM-CSF 4.8 _+ 0.7
H20 +__ GM-CSF 5.2 _+ 1.2
Piriprost _+ GM-CSF 5.0 _+ 1.0
0.2% DMSO _+ IL-8 5.6 _+ 2.0
MK-886 _+ IL-8 6.4 _+ 0.8
27.3 _+ 2.7 (506%)
26.1 -t- 1.9 (544%)
14.3 +_ 1.8 (275%)
18.3 + 3.2 (366%)
20.2 7.4 (361%)
19.8 _+ 7.1 (309%)
aCells were incubated with either 87 #M piriprost, 100 nM
MK-886 or diluent before the addition of GM-CSF (10 ng/ml)
or IL-8 (100 ng/ml), followed by stimulation with #M fMLP.
bThe absolute data shown are the mean + 1S.E. of seven
experiments with GM-CSF and three experiments with IL-8.
CSuperoxide production by samples trea.ted with cytokine was
expressed as a percentage of control (-cytokine) and is given
in parentheses.
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FIG. 3. Effect of 5-LO inhibition on the upregulation of CD11 b expression
stimulated by IL-8 and GM-CSF. Neutrophils were incubated with the
inhibitors (+1) 100 nM MK-886, 87 #M piriprost, or diluent, for 5 min
before stimulation with either 100ng/ml IL-8, 10 ng/ml GM-CSF, or
cytokine diluent. The mean cell fluorescence is given in arbitrary units.
Values shown are the mean of duplicate samples from single experiments,
representative of two that were performed. The range of the duplicate
samples was on average 20% of the mean./k, GM-CSF + I; ,, GM-CSF;
(C), IL-8 + I; O, IL-8; r-I, control + I; I, control.
Discussion
The authors have shown that both IL-8
and GM-CSF enhance or ’prime’ the Ca2+
ionophore-stimulated extracellular release of [3H]-
arachidonate metabolites from endogenous phos-
pholipid pools. This confirms previous studies
using GM-CSF.v-9 Daniels et al. is have recently
shown that IL-8 can prime the release of
[3H]arachidonate from cytochalasin B-treated neu-
trophils, however this fungal metabolite grossly
alters neutrophil phospholipid metabolism and is
itself a priming agent,iv
Using specific inhibitors of arachidonate 5-
lipoxygenase, piriprost,22 and the indole derivative,
MK-886,2 which specifically binds to the mem-
brane protein FLAP, inhibiting translocation of
5-LO and leukotriene production in intact cells,28
it has been demonstrated that the release of
[H]arachidonate metabolites from unprimed or
IL-8 primed neutrophils could be blocked by
greater than 90%. That these compounds inhibited
both the intracellular synthesis and extracellular
release of leukotrienes in unprimed and GM-CSF
primed cells was confirmed by RP-HPLC. In this
study the Ca2+ ionophore A23187 was used to
demonstrate the efficacy of these compounds
because it is the most potent stimulus for neutrophil
leukotriene production. The inhibition observed
with these compounds was not due to any toxic
et:fect because at the same concentrations neither
inhibited the generation of superoxide stimulated
by phorbol ester or fMLP.
The authors sought to determine whether
leukotrienes mediate the signal transduction or
priming activities of GM-CSF and IL-8. Previous
studies have shown little evidence for the
involvement of 5-LO in IL-8 signalling, but studies
of Rapoport et al. 6 have suggested a role for this
enzyme in GM-CSF signal transduction. Our data
exclude the possibility that leukotrienes function in
this respect, as the upregulation of cell adhesion
molecules directly stimulated by IL-8 and GM-CSF
was not altered by complete inhibition of 5-LO.
Priming of the fMLP stimulated respiratory burst
by IL-8 and GM-CSF was similarly unaffected by
inhibition of 5-LO.
It is concluded that leukotriene synthesis does
not mediate either the direct activity or the priming
eects of IL-8 and GM-CSF on mature neutrophils.
The study shows that while therapeutic treatment
of inflammation with 5-1ipoxygenase inhibitors will
inhibit leukotriene production by neutrophils
exposed to cytokines, it is unlikely to inhibit other
activities of these cytokines such as those associated
with upregulation of cell adhesion proteins,
degranulation, adhesion and migration, or increased
oxygen free-radical production.
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